Synopsis: Chemical stock hit the 20 percent upper circuit after reporting strong Q1 FY27 results, with revenue rising 43 percent YoY and net profit surging 140 percent, supported by broad-based business growth.
The share of this company, which is a manufacturer of a diverse portfolio of structure-directing agents, Phase Transfer Catalysts, electrolyte salts for batteries, pharmaceutical and Agrochemical Intermediates, and other Specialty chemicals, gained focus after posting strong Q1 numbers
With a market capitalization of Rs 4,010 crore, Tatva Chintan Pharma Chem Ltd’s share on Monday made a day high of Rs 1,714.10 per share, up by 20 percent, hitting upper circuit from its previous day’s close price of Rs 1,428.45 per share. The share of the company gave a return of 66 percent in the last year.
Result Overview
QoQ Performance
The revenue from operations grew by 25 percent QoQ to Rs 167.1 crore in Q1 FY27 from Rs 134.1 crore in Q4 FY26, and EBITDA grew by 15 percent to Rs 32.3 crore in Q1 FY27 from Rs 28.1 crore in Q4 FY26, while the EBITDA margin fell to 19 percent from 21 percent. This was accompanied by a PAT growth of 55 percent to Rs 16.0 crore in Q1 FY27 from Rs 10.3 crore in Q4 FY26, resulting in a PAT margin growth of 24 percent to 10 percent from 8 percent.
YoY Performance
The revenue from operations grew by 43 percent YoY to Rs 167.1 crore in Q1 FY27 from Rs 116.9 crore in Q1 FY26, and EBITDA grew by 86 percent to Rs 32.3 crore in Q1 FY27 from Rs 17.3 crore in Q1 FY26, with the EBITDA margin expanding to 19 percent from 15 percent. This was accompanied by a 140 percent increase in Profit After Tax to Rs 16.0 crore in Q1 FY27 from Rs 6.7 crore in Q1 FY26, resulting in a PAT margin expansion to 10 percent from 6 percent.
Which Segment drove the Q1 Performance?
Precision Aerospace and Specialty Components (PASC)
The PASC business remained the company’s biggest revenue contributor in Q1 FY27. It accounted for 35 percent of operating revenue, up from 32 percent in FY26, showing a stronger contribution from the aerospace and specialty components business.
Specialty Domestic Appliances (SDA)
The SDA segment contributed 34 percent of operating revenue in Q1 FY27, compared to 41 percent in FY26. While it remained one of the company’s key businesses, its share in the overall revenue mix declined during the quarter.
Precision Tubes and Components (PTC)
The PTC segment contributed 26 percent of operating revenue in Q1 FY27, up from 23 percent in FY26. The higher contribution shows that this business played a bigger role in the company’s overall revenue during the quarter.
Engineering Solutions and Services (ESS)
The ESS segment accounted for 4 percent of operating revenue in Q1 FY27, compared to 3 percent in FY26. Although it remained a small part of the business, the segment reported a slight improvement in its revenue contribution.
About the Company
Tatva Chintan, established in 1996, is a leading Indian company that specializes in manufacturing and R&D. The company, led by promoters Chintan Shah, Ajay Patel, and Shekhar Somani, has established a strong presence in various niche product categories such as Phase Transfer Catalysts, Structure Directing Agents, Electrolyte Salts and Solutions, and Pharmaceutical & Agrochemical Intermediates and Other Specialty Chemicals.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
